Tag: GLP-1 agonist

1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of patients achieving HbA1c targets of less than 7.0%. 2. Compared to placebo, the proportion of adverse events with tirzepatide were mildly elevated. Evidence Rating Level: 1 (Excellent) Study Rundown: In many patients...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to semaglutide alone. 2. Compared to control, combined cagrilintide and semaglutide improved glycemic parameters and mean body weight reduction at 20 weeks. Evidence Rating Level: 1 (Excellent)  Study Rundown: Semaglutide is a glucagon-like...
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients on semaglutide 2.4 mg achieved a target HbA1c of 6.5% or less.  Evidence Rating Level: 1 (Excellent) Study Rundown: There is strong overlap between weight gain and type 2 diabetes, with the...
1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to DPP-4 inhibitors or GLP-1 agonists. Evidence Rating Level: 2 (Good) Study Rundown: The sodium glucose cotransporter-2 (SGLT-2) inhibitors are a newer class of diabetic medications that act by inhibiting glucose reabsorption in...
1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to DPP-4 inhibitors or GLP-1 agonists. Evidence Rating Level: 2 (Good) Study Rundown: The sodium glucose cotransporter-2 (SGLT-2) inhibitors are a newer class of diabetic medications that act by inhibiting glucose reabsorption...